Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.03 | 0.55 | 0.25 |
| FCF Yield | -99.48% | -46.28% | -22.29% | -8.60% |
| EV / EBITDA | -0.84 | -1.23 | -2.05 | -9.11 |
| Quality | ||||
| ROIC | -429.43% | -87.65% | -43.53% | -34.13% |
| Gross Margin | 50.94% | 58.10% | 95.27% | -199.47% |
| Cash Conversion Ratio | 0.81 | 0.83 | 0.79 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.10% | 341.12% | 100.91% | 67.96% |
| Free Cash Flow Growth | 0.29% | -69.22% | 17.03% | -20.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.65 | 1.54 | 3.14 |
| Interest Coverage | -236.53 | -352.92 | -495.83 | -528.26 |
| Efficiency | ||||
| Inventory Turnover | 18.21 | 13.30 | 0.81 | 4.69 |
| Cash Conversion Cycle | -20.23 | -36.34 | -728.63 | 3,057.86 |